Photodynamic therapy for treatment of oral mucositis: Pilot study with pediatric patients undergoing chemotherapy

Silva, Vânia Cavalcanti Ribeiro da; Silveira, Fabiana Moura da Motta; Monteiro, Maria Gabriela Barbosa; Cruz, Mônica Moreira Dias da; Júnior, Arnaldo de França Caldas; Godoy, Gustavo Pina

doi:10.1016/j.pdpdt.2017.11.010

Cited by 44 publications

(29 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mucositis lesions are often extremely painful and may lead to oral discomfort, inadequate intake of food and medications, delays in cancer treatment, longer hospitalization time and consequently more costs and higher risk of life‐threatening infection . These complications may limit the patient's ability to tolerate an optimal antineoplastic treatment, which can negatively impact treatment planning and prognosis .…”

Section: Introductionmentioning

confidence: 99%

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Delavarian

Pakfetrat

Ghazi

et al. 2019

Special Care in Dentistry

View full text Add to dashboard Cite

Oral mucositis (OM) is a complication of head and neck cancer (HNC) therapy with negative impact on the quality of life. Although definitive treatment has not yet been established, there is interest towards the use of natural compounds owing to their few side effects. Curcumin has a variety of biological and pharmacological properties including anticancer and anti‐inflammatory effects. Aim The aim of this study is to evaluate the effect of curcumin in the form of nanomicelle on OM in HNC patients receiving radiotherapy. Methods In this clinical trial, 32 HNC patients were allocated to case and control groups, and respectively received nanocurcumin or placebo during radiotherapy. Results We found a statistically significant difference in the severity of mucositis between the 2 groups at all visits. In contrast to the control‐group patients, who all developed OM in the 2nd week of radiotherapy, only 32% of the case group developed OM with no obvious oral or systemic side effects. Conclusion Our data show that nanomicelle curcumin is an effective agent in the prevention of OM or reducing its severity. Thus, the administration of nanocurcumin can be considered as a reasonable approach to hinder the development of OM in HNC patients requiring radiotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Delavarian

Pakfetrat

Ghazi

et al. 2019

Special Care in Dentistry

View full text Add to dashboard Cite

show abstract

“…In a Brazilian study evaluating light‐based therapies for management of mucositis in children (10 months–18 years), ChIMES was collected by healthcare professionals and demonstrated a significant decrease in pain symptoms. (Ribeiro da Silva et al., 2018) An Indian study evaluating vitamin E and pycnogenol for treatment of oral mucositis in children demonstrated a significant reduction in ChIMES scores over the treatment period. (Khurana et al., 2013) Despite ChIMES not yet having been validated for use by healthcare professional proxy reporters, these studies demonstrate that there is interest in and need for such an instrument in pediatric oncology.…”

Section: Discussionmentioning

confidence: 99%

“…This implementation could be in the context of routine clinical care or within the design and conduct of clinical trials. (Immonen et al., 2020; Khurana et al., 2013; Ribeiro da Silva et al., 2018; Treister et al., 2017).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of healthcare professional proxy‐reported children’s International Mucositis Evaluation Scale

et al. 2021

View full text Add to dashboard Cite

Objective:The objective was to describe the reliability and validity of the healthcare professional proxy-report version of the Children's International Mucositis Evaluation Scale (ChIMES). Methods:We included pediatric patients who were between 4 and 21 years of age and scheduled to undergo hematopoietic cell transplantation. Mucositis was evaluated by trained healthcare professionals who scored ChIMES, the World Health Organization oral toxicity scale, mouth, and throat pain visual analogue scale, National Cancer Institute-Common Terminology Criteria and the Oral Mucositis Daily Questionnaire.Measures were completed daily and evaluated on days 7-17 post-stem cell infusion for this analysis. Psychometric properties examined were internal consistency, testretest reliability (days 13 and 14), and convergent construct validity.Results: There were 192 participants included. Cronbach's alpha was 0.90 for ChIMES Total Score and 0.93 for ChIMES Percentage Score. Test-retest reliability were as follows: intraclass correlation coefficient (ICC) 0.82 (95% confidence interval (CI) 0.77-0.85) for ChIMES Total Score and ICC 0.82 (95% CI 0.77-0.86) for ChIMES Percentage Score. In terms of construct validation, all correlations between measures met or exceeded those hypothesized (all p < 0.05). Conclusions:The healthcare professional proxy-report version of ChIMES is reliable and valid for children and adolescents undergoing hematopoietic cell transplantation.

show abstract

“…Studies investigating MB toxicity from the THERAFLEX plasma process from several European hemovigilance systems have indicated no increase in side effects . A recent pilot study reported the feasibility of using MB and laser treatment for relieving chemotherapy‐induced oral mucositis in children . We are not aware of any clinical studies that include children getting THERAFLEX products specifically, although they appear to be broadly used outside of the United States; the concerns about MB in neonatal patients have been well documented (described above).…”

Section: The Pediatric Experience With Pr/pi Blood Productsmentioning

confidence: 99%

Pathogen‐inactivated blood products for pediatric patients: blood safety, patient safety, or both?

Jacquot

Delaney

2018

Transfusion

View full text Add to dashboard Cite

show abstract

Photodynamic therapy for treatment of oral mucositis: Pilot study with pediatric patients undergoing chemotherapy

Cited by 44 publications

References 39 publications

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Oral administration of nanomicelle curcumin in the prevention of radiotherapy‐induced mucositis in head and neck cancers

Validation of healthcare professional proxy‐reported children’s International Mucositis Evaluation Scale

Pathogen‐inactivated blood products for pediatric patients: blood safety, patient safety, or both?

Contact Info

Product

Resources

About